|
|
|
|
| LEADER |
01677nam a22003015i 4500 |
| 001 |
000277897 |
| 005 |
20211028073207.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2008 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781597452748
|
| 024 |
7 |
|
|a 10.1007/978-1-59745-274-8
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Checkpoint Responses in Cancer Therapy /
|c edited by Wei Dai.
|
| 250 |
|
|
|a 1st ed. 2008.
|
| 260 |
# |
# |
|a Totowa, NJ :
|b Humana Press :
|b Imprint: Humana,
|c 2008.
|
| 300 |
|
|
|a XIV, 314 p. 33 illus., 3 illus. in color. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Cancer Drug Discovery and Development,
|
| 505 |
0 |
|
|a RB-Pathway -- Targeting the p53/MDM2 Pathway for Cancer Therapy -- DNA Topoisomerases as Targets for the Chemotherapeutic Treatment of Cancer -- Targeting ATM/ATR in the DNA Damage Checkpoint -- Compounds that Abrogate the G2 Checkpoint -- CDK Inhibitors as Anticancer Agents -- CHFR as a Potential Anticancer Target -- Antimicrotubule Agents -- Kinesin Motor Inhibitors as Effective Anticancer Drugs -- Targeting the Spindle Checkpoint in Cancer Chemotherapy -- Antiproliferation Inhibitors Targeting Aurora Kinases -- Plks as Novel Targets for Cancer Drug Design -- Do Histone Deacetylase Inhibitors Target Cell Cycle Checkpoints that Monitor Heterochromatin Structure?.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
1 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 700 |
1 |
|
|a Dai, Wei.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|